Magnetic Resonance Imaging-Transrectal Ultrasound Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate Cancer

• Published in: The Journal of urology Vol. 197; no. 3; pp. 640 - 646
• Main Authors: Frye, Thomas P, George, Arvin K, Kilchevsky, Amichai, Maruf, Mahir, Siddiqui, M. Minhaj, Kongnyuy, Michael, Muthigi, Akhil, Han, Hui, Parnes, Howard L, Merino, Maria, Choyke, Peter L, Turkbey, Baris, Wood, Brad, Pinto, Peter A
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-03-2017
• Subjects: Aged; biopsy; Disease Progression; Humans; Image-Guided Biopsy; magnetic resonance imaging; Magnetic Resonance Imaging, Interventional; Male; Middle Aged; Population Surveillance; Predictive Value of Tests; prostatic neoplasms; Prostatic Neoplasms - diagnostic imaging; Prostatic Neoplasms - pathology; Retrospective Studies; ultrasonography; Ultrasonography, Interventional; Urology; watchful waiting; multiparametric MRI; transrectal ultrasound; magnetic resonance imaging; PSAD; targeted biopsy; ultrasonography; MRI; fusion biopsy; prostate specific antigen; systematic biopsy; National Institutes of Health; NIH; TB; SB; AS; prostatic neoplasms; biopsy; MP-MRI; TRUS; FB; watchful waiting; active surveillance; PSA; PSA density
• ISSN: 0022-5347; 1527-3792
• DOI: 10.1016/j.juro.2016.08.109

Purpose Active surveillance is an established option for men with low risk prostate cancer. Multiparametric magnetic resonance imaging with magnetic resonance imaging-transrectal ultrasound fusion guided biopsy may better identify patients for active surveillance compared to systematic 12-core biopsy due to improved risk stratification. To our knowledge the performance of multiparametric magnetic resonance imaging in following men on active surveillance with visible lesions is unknown. We evaluated multiparametric magnetic resonance imaging and magnetic resonance imaging-transrectal ultrasound fusion guided biopsy to monitor men on active surveillance. Materials and Methods This retrospective review included men from 2007 to 2015 with prostate cancer on active surveillance in whom magnetic resonance imaging visible lesions were monitored by multiparametric magnetic resonance imaging and fusion guided biopsy. Progression was defined by ISUP (International Society of Urological Pathology) grade group 1 to 2 and ISUP grade group 2 to 3. Significance was considered at p ≤0.05. Results A total of 166 patients on active surveillance with 2 or more fusion guided biopsies were included in analysis. Mean followup was 25.5 months. Of the patients 29.5% had pathological progression. Targeted biopsy alone identified 44.9% of patients who progressed compared to 30.6% identified by systematic 12-core biopsy alone (p = 0.03). Fusion guided biopsy detected 26% more cases of pathological progression on surveillance biopsy compared to systematic 12-core biopsy. Progression on multiparametric magnetic resonance imaging was the sole predictor of pathological progression at surveillance biopsy (p = 0.013). Multiparametric magnetic resonance imaging progression in the entire cohort had 81% negative predictive value, 35% positive predictive value, 77.6% sensitivity and 40.5% specificity in detecting pathological progression. Conclusions Multiparametric magnetic resonance imaging progression predicts the risk of pathological progression. Patients with stable multiparametric magnetic resonance imaging findings have a low rate of progression. Incorporating fusion guided biopsy in active surveillance nearly doubled our detection of pathological progression compared to systematic 12-core biopsy.